Highlights Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 20:50:02 09/07/2025 BST			5-day change	1st Jan Change
5.015 ^USD	+3.19%		+2.76%	+4.91%

06-30	Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to Russell 2000 Value-Defensive Index	CI
06-30	Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to Russell 2000 Defensive Index	CI

Highlights

Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S	06-10	CI
Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-07	CI
Vanda Pharmaceuticals Inc. Reiterates Revenue Guidance for the Full Year 2025	05-07	CI
Vanda Pharmaceuticals Inc. Announces Bysanti NDA Filing	05-05	CI
Vanda Pharmaceuticals Seeks US FDA Approval for Bysanti to Treat Schizophrenia, Acute Bipolar I Disorder	03-31	MT
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti? for the Treatments of Acute Bipolar I Disorder and Schizophrenia	03-31	CI
Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate	03-17	MT
Vanda Pharmaceuticals Inc. Announces the Publication of an Article Article Entitled "Potential ASO-Based Personalized Treatment for Charcot-Marie-Tooth Disease Type 2S	02-24	CI
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	02-13	CI
Vanda Pharmaceuticals Inc. Provides Revenue Guidance for the Year 2025 and 2030	02-13	CI
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab	02-03	CI
Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab	02-03	MT
Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab	02-03	RE
Vanda Pharmaceuticals Inc. Accepts FDA Opportunity for A Hearing on New Drug Application for Tradipitant in Gastroparesis	01-27	CI
Vanda Pharmaceuticals' Prospective Treatment for Blood Cancer Receives US FDA's Orphan Drug Designation	12-20	MT
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q3 Revenue $47.7M	11-06	MT
Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024	11-06	CI
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-06	CI
HC Wainwright Starts Vanda Pharmaceuticals With Buy Rating, $18 Price Target	31/10/24	MT
Global markets live: InPost, Nvidia, Coty, Verizon, Apple...	15/10/24
Sector Update: Health Care Stocks Rise Late Afternoon	14/10/24	MT
Sector Update: Health Care Stocks Higher Monday Afternoon	14/10/24	MT
Vanda Pharmaceuticals Shares Rise; Cycle Pharmaceuticals' Buyout Offer Rejected Again	14/10/24	MT
Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer	14/10/24	RE
Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million.	13/10/24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Highlights

Filters